The processes in the brain and body through which physical exercise reduces depressive symptoms have been explored by UCL researchers. Depression is the leading cause of disability worldwide… read more.
Roche announced that the European Commission (EC) has approved Vabysmo (faricimab) for the treatment of visual impairment due to macular edema secondary to retinal vein occlusion (RVO, branch… read more.
A landmark study from researchers at Huntsman Cancer Institute at the University of Utah (the U), the Spencer Fox Eccles School of Medicine at the U, and Boston University Chobanian & Avedisian School of Medicine found… read more.
Osteoarthritis affects 600 million people worldwide, making it a leading cause of disability. With no disease-modifying treatments available or on the horizon, oral non-steroidal anti-inflammatory drugs (NSAIDs) are… read more.
Pfizer Inc. announced that the European Commission (EC) has granted conditional marketing authorization for Durveqtix (fidanacogene elaparvovec), a gene therapy for the treatment of severe and moderately severe… read more.
More than 82% of Americans age 50 to 80 take one or more kinds of prescription medication, and 80% of them say they’d be open to stopping one… read more.
On 25 July 2024, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the granting of a marketing authorisation for the medicinal product… read more.
There’s limited evidence to back up the widespread and increasing rates of prescribing mood-altering drugs (psychotropics) as the mainstay of mental health treatment for children and young people,… read more.
Sun Pharmaceutical Industry announced that the FDA approved Leqselvi (deuruxolitinib) 8 mg tablets for the treatment of adults with severe alopecia areata. Alopecia areata affects around 700,000 people… read more.
The US Surgeon General recently recommended a warning label for social media platforms due to concerns about their impact on youth mental health. The Surgeon General’s Advisory on… read more.
Prescribing non-steroidal anti-inflammatory drugs (NSAIDs) to people at high risk of harm from them is estimated to cost the NHS in England around £31 million and cause more… read more.
GSK plc announced that ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer and Shionogi as shareholders, has shared 48-week findings from the PASO… read more.
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.
